Diplomat Pharmacy (DPLO) Tops Q2 EPS by 4c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Diplomat Announces 2nd Quarter 2015 Financial Results
August 3, 2015 4:05 PM EDTFLINT, Mich., Aug. 3, 2015 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended June 30, 2015. All comparisons, unless otherwise noted, are to the quarter ended June 30, 2014.
Second Quarter 2015 Highlights include:
Revenue of $808 million, an increase of 49% or $266 million Total prescriptions dispensed of 234,000, an increase of 19% Gross margin of 8.6% versus 5.5% Adjusted EBITDA of $22.7 million, an increase of 287% or $16.8 million Adjusted EPS of... More